Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023

GAITHERSBURG, Md., Nov. 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Thursday, November 9, 2023. Details of the event and replay are as follows:

Conference call details:
Date:	November 9, 2023
Time:	8:30 a.m. U.S. EST
Dial-in number:	[phone] (Domestic) or [phone] (International)
Passcode:	1754341
Webcast:	ir.novavax.com/events

• Participants will be prompted to request to join the Novavax, Inc. call.
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.

Replay details:
Date:	Available starting at 11:30 a.m. EST, November 9, 2023, until 11:59 p.m. U.S. EST, November 16, 2023
Dial-in number:	[phone] (Domestic) or [phone] (International)
Passcode:	5567#
Webcast:	ir.novavax.com/events, until February 7, 2024

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.

Contacts: 
Investors
Erika Schultz
240-268-2022
[e-mail]

Media
Ali Chartan
240-720-7804
[e-mail]

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-third-quarter-2023-financial-results-and-operational-highlights-on-november-9-2023-301974716.html

SOURCE NOVAVAX, INC

Copyright 2023 PR Newswire